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ABSTRACT
A series of HeLa cell lines which stably express b-globin pre-mRNAs carrying point mutations at nt 654, 705, or 745
of intron 2 has been developed. The mutations generate aberrant 5 9 splice sites and activate a common 3 9 cryptic
splice site upstream leading to aberrantly spliced b-globin mRNA. Antisense oligonucleotides, which in vivo blocked
aberrant splice sites and restored correct splicing of the pre-mRNA, revealed major differences in the sensitivity of
these sites to antisense probes. Although the targeted pre-mRNAs differed only by single point mutations, the
effective concentrations of the oligonucleotides required for correction of splicing varied up to 750-fold. The differ-
ences among the aberrant 5 9 splice sites affected sensitivity of both the 5 9 and 39 splice sites; in particular, sensitivity
of both splice sites was severely reduced by modification of the aberrant 5 9 splice sites to the consensus sequence.
These results suggest large differences in splicing of very similar pre-mRNAs in vivo. They also indicate that anti-
sense oligonucleotides may provide useful tools for studying the interactions of splicing machinery with pre-mRNA.
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INTRODUCTION
Pre-mRNA splicing takes place in a multicomponent
complex, the spliceosome, which forms de novo during
each splicing event and disintegrates to its constituent
components after the splicing reaction has been com-
pleted+ In the early steps, the pre-mRNA sequences at
the 59 splice site and at the branch point are base
paired with the 59 end of small nuclear RNA U1 (U1
snRNA) and the internal portion of U2 snRNA, respec-
tively+ These RNAs are each complexed with a number
of proteins forming ribonucleoprotein particles (snRNPs)+
In addition to U1 and U2, the functional spliceosome
includes U4/U6+U5 triple snRNP and a number of other
protein splicing factors+ Altogether, the relatively short
sequences at the splice sites and the branchpoint in-
teract with or are in proximity to five snRNAs and at
least seventy proteins (reviewed in Moore et al+, 1993;
Krämer, 1996; Reed, 1996; Will & Lührmann, 1997;
Staley & Guthrie, 1998)+
The structure of the spliceosome described above
appears to be only rudimentary and for multi-intron
pre-mRNAs may be even more complex+ Efficient rec-
ognition of internal, especially alternative, splice sites
is enhanced by additional sequences, so called exonic
or intronic splicing enhancers+ On the other hand, par-
tial, that is, inefficient splicing of retroviral genomic RNAs
requires suboptimal splice sites and/or splicing silenc-
ers+ In either case these pre-mRNA sequences are
bound by protein factors that in turn interact with com-
ponents of the canonical spliceosome, for example,
U2AF or U1 70K proteins+ The splicing factors that are
responsible for the enhancer/silencer activity usually
belong to a family of SR-proteins that share an arginine-
serine domain as well as RNA binding domains (Man-
ley & Tacke, 1996; McNally & McNally, 1996; Valcarcel
& Green, 1996; Hertel et al+, 1997; Wang & Manley,
1997)+ SR-proteins appear to be part of a larger group
of splicing factors in which arginines may alternate with
amino acids other than serines (Blencowe et al+, 1995;
Neugebauer et al+, 1995)+ Thus, the components of the
spliceosome may be even more numerous than was
initially believed+ Moreover, pre-mRNA sequences that
interact with splicing factors extend well beyond the
splice sites and the branch point+
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There is compelling evidence that exons are the se-
quence elements initially recognized in multi-intron pre-
mRNAs (Berget, 1995)+ Binding of U1 snRNP to the
downstream 59 splice site and of U2 snRNP to the
branchpoint in the upstream intron is stabilized by a
series of RNA–protein and protein–protein interactions
across the exon+ For example, purine rich splicing en-
hancers bind SR-proteins such as ASF/SF2 or SC35,
which in turn bridge the exon and stabilize the splicing
complex by protein–protein interactions with U1 70K
subunit and U2AF (Manley & Tacke, 1996; Hertel et al+,
1997)+ Exon recognition is promoted not only by purine
rich enhancers but also by a variety of other sequences
(Dominski & Kole, 1994a; Staknis & Reed, 1994; Tian
& Kole, 1995; Coulter et al+, 1997) suggesting that nu-
merous protein factors, presumably members of the
SR and SR-like families,may be involved in exon bridg-
ing+ Hence, as judged mostly from in vitro experiments,
during splicing of various exons the composition of the
spliceosomes and/or their interactions with pre-mRNA
may differ significantly+
We have investigated point mutations at positions 654,
705, and 745 of intron 2 of the human b-globin gene
(IVS2-654, IVS2-705, IVS2-754) that create additional
59 splice sites within the intron at or in close proximity to
the mutation site (Treisman et al+, 1983; Cheng et al+,
1984; Dobkin & Bank, 1985)+ Each mutation also acti-
vates a cryptic 39 splice site at position 579 resulting in
the insertion of an aberrant, exon-like sequence of, re-
spectively, 73, 126, or 165 nt into the spliced b-globin
mRNA (Fig+ 1A)+ The insertions generate a stop codon
(Fig+ 1B) preventing proper translation of the mRNA and
causing b-thalassemia, a genetic disorder (Schwartz &
Benz, 1995)+Even though the correct splice sites still ex-
ist in all three mutants, the splicing pathways are shifted
to aberrant ones because of the creation of internal ab-
errant exons by the thalassemic mutations+
In nuclear splicing extracts, blocking of the aberrant
59 splice sites or the cryptic 39 splice site activated by
the IVS2-654 and -705 mutations in b-globin pre-mRNA
with 29-O-methyl-oligoribonucleotides reversed aber-
rant and restored correct splicing+ The concentrations
of the oligonucleotides required for 50% correction of
splicing (EC50) in both 654 and 705 mutated pre-mRNA
was approximately 0+1 and 0+2 mM for the 59 and 39
splice sites, respectively, indicating that the sensitivity
of the splice sites to the oligonucleotides was quite
similar (Dominski & Kole, 1993)+ The results presented
below show that the sensitivity of the same sequences
to the oligonucleotides in vivo, in HeLa cells constitu-
tively expressing thalassemic b-globin pre-mRNAs, dif-
fers markedly in the IVS2-654, -705, and -745 mutants+
RESULTS
To test the in vivo effects of antisense oligonucleotides,
HeLa based cell lines stably expressing human thalas-
semic b-globin genes IVS2-654, -705, and -745 driven
by the CMV promoter were generated by cotransfection
with plasmids carrying the appropriate globin gene and
the neomycin resistance marker+ The stably transfected
cells were treated with complexes of Lipofectamine and
17 or 18-mer 29-O-methyl-oligoribonucleoside phospho-
rothioates (Table 1) targeted to the aberrant splice sites
resulting from a given mutation (see Sierakowska et al+,
1996 and Materials and Methods)+
Correction of splicing of IVS2-654 pre-mRNA
by antisense oligonucleotide, ON-654
The results of treatment of IVS2-654 HeLa cells with oli-
gonucleotide ON-654, targeted to the aberrant 59 splice
site created by the mutation, are illustrated in Fig-
ure 2+Analysis of total cellular RNAby RT-PCR (see Ma-
terials and Methods) showed that the oligonucleotide
FIGURE 1. A: Splicing of human b-globin IVS2 mutant pre-mRNAs+
Numbered boxes: exons; shaded lines: introns+ Dashed lines indi-
cate both correct and aberrant splicing pathways+ The aberrant 59
splice sites created by IVS2-654, -705, and -745 mutations and the
cryptic 39 splice site activated upstream are indicated+ Shaded bar:
oligonucleotide antisense to the aberrant 39 splice site+ Solid lines
marked a, b, and c indicate primers used in the RT-PCR reaction+ B:
Sequence of b-globin and mutant spliced mRNAs+ For b-globin mRNA
a fragment of the sequence across the splice junction between ex-
ons 2 and 3 is shown in upper case+ Sequences for mutant RNAs
include aberrant exons (lower case)+ The stop codon generated by
the three mutations is shown in bold+
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restored correct splicing of the b-globin mRNA in a dose
dependent manner (Fig+ 2, lanes 2–6)+ At 0+2 mM ex-
tracellular concentration of the oligonucleotide, the
maximum amount (approximately 48%, see Materials
and Methods for quantitation of the results) of the
b-globin RNAwas converted to the correctly spliced form
(Fig+ 2, lane 4)+Note that the maximum uptake of the oli-
gonucleotide into the cell requires a specific charge ra-
tio between the negatively charged oligonucleotide and
the positively charged Lipofectamine (Hawley-Nelson
et al+, 1993; Bennett, 1998)+ This charge ratio was ex-
ceeded at 0+4 and 0+6 mM concentration of the oligo-
nucleotide leading to a decrease in the correction of
splicing (Fig+ 2, lanes 5 and 6)+ However, the design of
this experiment allows for determination of the true
maximal effect under given experimental conditions+The
effects are strictly sequence specific since a number
of control oligonucleotides such as those with random
sequence, mismatch, or targeted to regions of the in-
tron distant from the splicing elements were ineffective
(Sierakowska et al+, 1996; Kang et al+, 1998, and data
not shown)+
Correction of splicing of IVS2-705
and IVS2-745 pre-mRNAs
by antisense oligonucleotides
Correction of splicing of HeLa cell line IVS2-705 pre-
mRNA with ON-705 oligonucleotide was much easier
to achieve than that in the IVS2-654 cell line with
ON-654+ Correctly spliced b-globin mRNA was easily
detectable at 1 nM ON-705, (Fig+ 3A, upper panel,
lane 3) and at 50–200 nM, correction of splicing was
essentially complete (Fig+ 3A, lanes 6 and 7)+ As in
the IVS2-654 experiment, higher concentrations of the
oligonucleotide led to a decrease in correction of splic-
ing (Fig+ 3A, lanes 9 and 10)+ The sequence speci-
ficity of these effects was shown by the lack of
correction of splicing in cells treated with a random
sequence oligonucleotide (ON-ran) in a broad range
of concentrations (Fig+ 3A, lower panel) or with mis-
matched oligonucleotides (data not shown)+
To ascertain that the RT-PCR assay does not over-
estimate the concentration of the newly generated cor-
rectly spliced b-globin mRNA, the total protein from
oligonucleotide-treated IVS2-705 HeLa cells was as-
sayed by immunoblotting with an anti-human hemoglo-
bin antibody (see Materials and Methods)+ In agreement
with the results shown in Figure 3A, upper panel, high
levels of the b-globin polypeptide were detected in cells
treated with 50–400 nM ON-705 (Fig+ 3B, lanes 7–9)+
b-Globin was easily detected even at 3–10 nM ON-705
(Fig+ 3B, lanes 5 and 6)+ Thus, generation of the globin
protein confirms that correction of splicing of IVS2-705
pre-mRNAs takes place at a significantly lower con-
centration of antisense oligonucleotides than that of
IVS2-654 pre-mRNA (see also Fig+ 1 in Sierakowska
et al+, 1996)+
TABLE 1 + Antisense oligonucleotides+
Oligonucleotide Sequence %GC Tm (8C)a
ON-654 GCU AUU ACC UUA ACC CAG 44 46
ON-654con GCA GUU GCC UUA ACC CAG 56 50
ON-705 CCU CUU ACC UCA GUU ACA 44 46
ON-745 GAA UGG UAC CUG GAU UGU 44 46
ON-39CR CAU UAU UGC CCU GAA AG 41 42
aTm values were calculated for oligodeoxynucleotides and not for the 29-O-methyl
phosphorothioate derivatives+ Nevertheless, they indicate the relative hybridization poten-
tial of the modified oligonucleotides used in this study+
FIGURE 2. Correction of splicing of IVS2-654 pre-mRNA in HeLa
cells by antisense oligonucleotide, ON-654, targeted to the aberrant
59 splice site+ Analysis of total RNA by RT-PCR with forward and
reverse primers a and c, respectively (see Materials and Methods
and Fig+ 1A)+ Unless otherwise indicated these primers are used in
subsequent figures+ Lane 1: untreated HeLa cells; lanes 2–6: IVS2-
654 HeLa cells treated with increasing concentrations of the oligo-
nucleotide (in mM, indicated at the top); Lane 7 (Hb): RNA from
human blood+ In this and subsequent figures the numbers on the left
indicate the size, in nucleotides, of the RT-PCR products represent-
ing the aberrantly (304) and correctly (231) spliced RNAs+ Note that
RT-PCR was carried out in the presence of a[32P]-ATP and that the
adenosine nucleotide content in the aberrantly spliced product is
1+57 times that of the correctly spliced one+ Thus, the degree of
correction is higher than it appears from the autoradiogram (see
Materials and Methods)+
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Restoration of correct splicing of IVS2-745 pre-mRNA
was even more efficient than in the other two mutants+
At 10 nM ON-745 oligonucleotide, only correct b-globin
mRNA was detected (Fig+ 4, lane 3)+ Interestingly, al-
though the aberrantly spliced RNA was no longer de-
tectable, the level of b-globin mRNA increased in a
dose dependent manner at 30–300 nM ON-745 (Fig+ 4,
lanes 5–7)+ A likely interpretation of this result is that
the stability of the correct b-globin mRNA is higher than
that of its aberrantly spliced 745 counterpart and there-
fore the product of correct splicing of IVS2-745 pre-
mRNA accumulates at a higher steady state level+
Analysis of IVS2 mutants and oligonucleotides
Quantitation of the results shown in Figures 2–4 and of
additional experiments and the linear regression analy-
sis of the oligonucleotide concentration shows that the
EC50 of the oligonucleotides targeted to the three ab-
errant 59 splice sites differs by up to 115-fold (Table 2
and Materials and Methods)+ Several lines of evidence
indicate that the difference in the sensitivity of the tar-
geted splice sites is an intrinsic property of the spliced
pre-mRNAs and is not due to variations of the oligo-
nucleotides and/or the cell lines+ The levels of aber-
rantly spliced RNAs decrease significantly in the order
IVS2-654, -705, -745 (compare lane 1 in Figs+ 2, 3A,
and 4) suggesting that expression of the thalassemic
genes could be different in the three cell lines+ Conse-
quently, the ratio of the oligonucleotide to the pre-
mRNA target could be much higher in IVS2-705 and
-745 than in IVS2-654 cells+ This higher ratio would
favor hybridization of the oligonucleotides, promoting
correction of splicing+ However, the level of b-globin
pre-mRNA, assayed by RT-PCR of total cellular RNA,
was found to be lowest in the IVS2-654 cell line, inter-
mediate in -705, and the highest in -745 (Fig+ 5, upper
panel, lanes, 2, 3, and 5; the construct IVS2-654con,
lane 4, is discussed in the subsequent section)+ A con-
trol PCR reaction, with the reverse transcription step
omitted, shows that these results are not due to geno-
mic DNA, a possible contaminant of the RNA prepara-
tion (Fig+ 5, lower panel)+ This indicates that correction
of splicing of IVS2-654 pre-mRNA was the least effi-
cient in spite of the most favorable ratio of the anti-
sense oligonucleotide to its target (see also Discussion)+
Although the 18-mer oligonucleotides ON-654, -705,
and -745 differ in sequence, their hybridization poten-
tial, as reflected by their GC content and Tm values
(Table 1), is identical and hence unlikely to be res-
ponsible for the observed differences in correction of
splicing+ The secondary and/or tertiary structure of the
pre-mRNAs around the targeted splice sites is also
unlikely to differentially affect access of the oligonucle-
FIGURE 3. A: Correction of splicing in IVS2-705 HeLa cell line+
Upper panel: treatment of cells with ON-705 oligonucleotide+ Lower
panel: treatment of IVS2-705 HeLa cells with random sequence
oligonucleotide (ON-ran) as sequence specificity control+ All other
designations are as in Figure 2+ B: Restoration of b-globin expres-
sion by ON-705 oligonucleotide in IVS2-705 HeLa cells+ Immuno-
blot of total cellular protein probed with anti-human hemoglobin
antibody+ Lanes 1 and 10: human globin (Hb) (Sigma) used as a
marker; lane 2: untreated cells; lanes 3–9: cells treated with in-
creasing concentrations (in mM, indicated at the top) of ON-705+
FIGURE 4. Correction of splicing in IVS2-745 HeLa cell line+ Treat-
ment of cells with ON-745+ All designations are as Figure 2+
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otides+Computer analysis (Jaeger et al+, 1989;Wiscon-
sin Package,V+ 9+1) of the folding of IVS2-654, -705, and
-745 introns, which vary only by single point mutations,
did not reveal any obvious differences (not shown)+
Splicing of thalassemic pre-mRNA in two different
clones of HeLa IVS2-654 and three different clones of
HeLa-705 cells showed similar differences in sensitiv-
ity to ON-654 and ON-705 nucleotides, respectively, as
well as to the 39-cryptic splice site oligonucleotide com-
mon to all three mutants (data not shown, see also
below)+ These differences were retained in two inde-
pendent clones of IVS2-654 and two of IVS2-705 cell
lines based on erythroid, K-562 cells (L+ Gorman and
R+ Kole, unpubl+)+ Likewise, the differences in sensitiv-
ity between IVS2-654, -705, and -745 were observed
in cells transfected with U7 snRNAs targeted to the
aberrant splice sites (Gorman et al+, 1998 and unpubl+
data)+ Furthermore, 3T3 IVS2-654 cells (Sierakowska
et al+, 1996) showed sensitivity to ON-654 characteris-
tic of the HeLa and K562 IVS2-654 cells+ These obser-
vations exclude the possibility that the selected clonal
cell lines might have differed in their ability to uptake
the oligonucleotides or in other properties that affected
the results but which were unrelated to the splicing
mutations in the b-globin pre-mRNA+
FIGURE 5. Expression of mutant IVS2 pre-mRNAs in HeLa cell lines+
Total RNA from IVS2-705 (lane 2), -654 (lane 3) -654con (lane 4),
and -745 (lane 5) cells was subjected to RT-PCR (upper panel) with
forward and reverse primers a and b, respectively (see Materials and
Methods and Fig+ 1A)+ In lane 1, as size marker control, DNA from a
plasmid carrying a human b-globin gene was also subjected to RT-
PCR+ In lower panel, the reverse transcription step was omitted and
the samples were subjected to PCR only+ Only traces, if any, of
contaminating DNA were detected in the RNA samples+
TABLE 2 + Effective concentration of antisense oligonucleotides targeted to IVS2
mutant pre-mRNAs+
EC50 (nM)b
Pre mRNA 59 splice site U1a 59c 39cr
IVS2-654 CUGGGUUAAG/GUAAUAGC 115 1,560
|| |||| |
U1 GUC/CAUUCAUA 7/11
IVS2-705 UGUAACUGAG/GUAAGAGG 4 31
|| ||||| |
U1 GUC/CAUUCAUA 8/11
IVS2-745 UACAAUCCAG/GUACCAUU 1 2
||| ||| |
U1 GUC/CAUUCAUA 7/11






39 cryptic splice site
All RNAs UUUCAG/GGCAAUAAUG
aAs a measure of splice site strength, the number of nucleotides within the splice site
that base pair with the 59 end of U1 snRNA is shown+ The relevant fragment of U1
sequence is shown under the splice site sequence+
bConcentration of an oligonucleotide that restored 50% of correct splicing was cal-
culated as described in Materials and Methods+
c59 denotes oligonucleotides targeted to the aberrant 59 splice sites of the respective
IVS2 mutants, that is, ON-654 targeted to IVS2-654 pre-mRNA, ON-705 targeted to
IVS2-705 pre-mRNA, and so forth+ 39cr denotes ON-39cr oligonucleotide targeted to the
cryptic 39 splice site common to all IVS2 mutants+ The sequences of the oligonucleo-
tides are listed in Table 1+
dCorrection of splicing was not detectable+
Variability of pre-mRNA splicing 373
Targeting the cryptic 3 9 splice site with ON-3 9cr
The fact that the same cryptic splice site is activated by
IVS2-654, -705, and -745 mutations allows for design-
ing a single oligonucleotide that should modify the splic-
ing pathways in all the three pre-mRNAs+ This approach
eliminates any possible effects of the variations in oli-
gonucleotide and target sequences inherent in the above
experiments+ Thus, the extent of splicing correction for
each pre-mRNA must reflect the sensitivity of the target
sequence to the oligonucleotide+
Figure 6 shows that in spite of the fact that the same
17-mer oligonucleotide (ON-39cr, Table 1) binds to the
same target sequence, the extent of correction of splic-
ing differs significantly for each of the mutant RNAs and
that the results follow the trend seen for the oligonucle-
otides targeted to the aberrant 59 splice sites+ The HeLa
IVS2-654 cell line was highly resistant to treatment with
ON-39cr oligonucleotide and only minor quantities of cor-
rectly spliced b-globin mRNA could be detected at 0+1
and 0+2 mM oligonucleotide (Fig+ 6A, lanes 3 and 4, re-
spectively)+ In contrast, treatment of the HeLa IVS2-705
cell line with ON-39cr corrected splicing close to 70% at
0+1 mM (Fig+ 6B, lane 7)+ Correction of splicing of IVS2-
745 pre-mRNA by ON-39cr was very effective and was
complete at 0+03 mM oligonucleotide (Fig+ 6C, lane 5)+
Remarkably, EC50 of ON-39cr varies from 1+5 mM for the
IVS2-654 mutant to 2 nM for IVS2-745, a range of al-
most three orders of magnitude (Table 2)+
Splice site strength versus sensitivity
to oligonucleotides
Analysis of the data in Table 2 for IVS2-654, -705, and
-745 may suggest, paradoxically, that sensitivity of the
59 splice sites to the oligonucleotides is not related to
the predicted splice site strength+ Judging by the po-
tential of the various 59 splice sites to base pair with U1
snRNA (Table 2) or by calculation (Senapathy et al+,
1990) of their match to the consensus splice site se-
quence (data not shown), the IVS2-654 59 splice site is
expected to be weaker than IVS2-705 and of equal
strength with IVS2-745+ Nevertheless, the IVS2-654
splice site was found to be 29- and 115-fold less sen-
sitive than its -705 and -745 counterparts, respectively
(Table 2)+ To investigate the mechanisms that may gov-
ern the response of the splice sites to oligonucleotides,
we have modified the noncanonical but relatively inac-
cessible IVS2-654 59 splice site (AAG/GUAAUA) to a
consensus splice site (AAG/GUAAGU in IVS2-654con
pre-mRNA, Table 2)+ The near-perfect but sensitive
IVS2-705 59 splice site was also converted to a con-
sensus sequence IVS2-705con (GAG/GUAAGA to
GAG/GUAAGU, respectively)+
Treatment of the IVS2-654con HeLa cell line with
0+2 and 0+4 mM ON-654con led to barely detectable
correction of splicing (Fig+ 7, lanes 9 and 10, respec-
FIGURE 6. Treatment of IVS2-654 (A), -705 (B), and -745 (C) HeLa
cell lines with ON-39cr oligonucleotide+ This oligonucleotide targets
the 39 cryptic splice site common to the three mutant pre-mRNAs+All
designations are as in Figure 2+
FIGURE 7. Poor accessibility of the aberrant splice sites in IVS2-
654con pre-mRNA+ HeLa cells expressing IVS2-654con pre-mRNA
were treated with ON-39cr (lanes 2–5) or ON-654con (lanes 7–10)+
Only minimal correction of splicing was observed in lanes 9 and 10+
Lanes 1 and 6: untreated cells; lane 11: RNA from human blood+
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tively) while ON-39cr failed to correct splicing at any
of the tested concentrations of the oligonucleotide
(Fig+ 7, lanes 2–5)+ Since the level of aberrantly spliced
b-globin RNA was high, it raised the possibility that
strong expression of the IVS2-654con pre-mRNA might
have led to an unfavorable ratio of the target pre-
mRNA to the oligonucleotides+ However, analysis of
the RNA shown in Figure 5 (lane 4, upper panel)
indicates that the cellular level of IVS2-654con pre-
mRNA was actually lower than that in the other cell
lines+ Thus, the change in the 59 splice site, which
increased its match to the consensus and comple-
mentarity to U1 snRNA, must have been responsible
for decreased sensitivity of this sequence to the oli-
gonucleotide+ Interestingly, the change in the IVS2-
654 59 splice site eliminated correction of splicing by
ON-39cr, targeted to the upstream 39 splice site, indi-
cating that there is interplay between the splice sites+
Modification of the relatively strong IVS2-705 splice
site to a consensus sequence in IVS2-705con con-
struct also supports the above conclusions+ Although,
in contrast to IVS2-654con cells, correct b-globin
mRNA was easily detected in IVS2-705con HeLa cells
treated with ON-39cr oligonucleotide, its amount was
decreased in comparison to IVS2-705 cells+ The EC50
of ON-39cr for IVS2-705con was 133 nM, approxi-
mately fourfold higher than for IVS2-705 cells (31 nM,
Table 2)+ Clearly, changes in the 59 splice site affect
not only its sensitivity to the oligonucleotides but also
that of the upstream 39 splice site+ The differences
between the IVS2-654 and IVS2-705 cell lines and
their consensus derivatives suggest that additional se-
quence elements of the aberrant internal exons mod-
ulate splice site sensitivity (see Discussion)+
DISCUSSION
The IVS2-654, -705, and -745 mutant pre-mRNAs dif-
fer only by single nucleotides and functionally share
the upstream intron, the 39 splice site and the first 75 nt
of the aberrant exon+ In the first two mutants the aber-
rant exon is fully included in the spliced message
whereas in the third one, its inclusion is partial but still
quite efficient+ However, application of antisense oligo-
nucleotides for in vivo probing of splicing pathways in-
dicates that in spite of their sequence and functional
similarities, the mutated pre-mRNAs show major differ-
ences in their interactions with the oligonucleotide
probes+ This is best illustrated by the 750-fold differ-
ence in the response of the 39 splice site in IVS2-654
versus IVS2-745 pre-mRNAs to the antisense oligonu-
cleotide, ON-39cr+ The experiments presented in this
report show that these differences are due to the na-
ture of splicing mutations in b-globin pre-mRNA and
not to the variability in cellular background or in oligo-
nucleotide uptake or efficacy+ Two possible mecha-
nisms may be responsible for this phenomenon: the
differences in the rates of pre-mRNA splicing or in the
accessibility of the splice sites to the oligonucleotides+
The levels of mutant pre-mRNAs, the targets for oli-
gonucleotides, are low in IVS2-654 and IVS2-654con
cell lines, in which correction of splicing is difficult, and
higher in the easily correctable IVS2-705 and IVS2-745
cell lines+ Assuming that the rate of b-globin RNA tran-
scription, driven in all cell lines by the CMV promoter, is
similar, the low levels of poorly correctable pre-mRNAs
suggest that these RNAs are spliced at a high rate+ If
the hybridization of the oligonucleotides to the target
sequences were much slower than the rate of pre-
mRNA splicing, blocking of the aberrant splice sites by
the oligonucleotides, and, in consequence, the shift of
the splicing pathway from aberrant to correct might be
disfavored+ If the rates of aberrant splicing and oligo-
nucleotide hybridization were not significantly different,
however, then poor correction of efficiently spliced pre-
mRNAs would suggest that their splice sites were not
accessible to the oligonucleotides, presumably be-
cause of steric hindrance of strongly bound splicing
factors+ Note that in the latter scenario, the low levels of
pre-mRNA result in a high ratio of oligonucleotides to
their targets, which could be expected to promote hy-
bridization and splicing correction+ Although the exper-
iments do not distinguish between the kinetic or steric
hindrance mechanisms, both must be due to the differ-
ences in the interactions of the splicing factors with the
splice sites and/or other sequence elements in the
b-globin pre-mRNAs+ It follows that the effective con-
centration of the oligonucleotides (EC50) necessary for
correction of splicing provides a quantitative, although
indirect, measure for the strength of binding of the el-
ements of the spliceosome to their target sequences+
It appears that the strength of the aberrant 59 splice
sites and the distance between the 39 and the 59
splice sites flanking the internal exons determine the
differences in EC50 of oligonucleotides+ For example,
replacement of IVS2-654 59 splice site with a consen-
sus sequence, IVS2-654con, increased EC50 of oligo-
nucleotides 12-fold, from 115 nM for ON-654 to 1,420
nM for ON-654con (Table 2)+ This is in spite of the
fact that ON-654con has the highest GC content and
Tm of all the oligonucleotides tested (Table 1) and
therefore is expected to have the highest affinity to
its target sequence+ However, oligonucleotide sensi-
tivity of the 59 splice sites correlates better with the
length of the aberrant, upstream exon (IVS2-654 ,
-705 , -745) than with the splice-site strength de-
fined either as a match to the 59 splice site consen-
sus sequence (IVS2-705 . -654 . -745; data not
shown, Senapathy et al+, 1990) or in terms of the
number of base-pairs formed with U1 snRNA (IVS2-
705 . -654 5 -745; Table 2)+ Since the variable part
of the internal exons does not seem to contain typi-
cal splicing enhancers or silencers (Fig+ 1B), it seems
likely that it is the length of the aberrant exon that
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modulates its recognition+ The effects of exon length
on splicing efficiency and exon inclusion both in vitro
and in vivo have been recognized previously (Reed
& Maniatis, 1986; Furdon & Kole, 1988; Dominski &
Kole, 1991; Sterner & Berget, 1993)+ Nevertheless,
the fact that aberrant exons IVS2-654 and IVS2-705,
which in vivo are both fully included into the spliced
product, differ in their respective sensitivity to the anti-
sense oligonucleotides at the 59 splice site by 29-fold
was surprising+ Note that a trace of correctly spliced
product is detectable in untreated IVS2-705 but not
in IVS2-654 HeLa cells (cf+ lanes 1 in Figs+ 3 and 2,
respectively)+ Thus the efficiency of exon inclusion and
its sensitivity to oligonucleotides are in qualitative if
not quantitative agreement+ A similar correlation was
observed in vitro in cell-free extracts (Dominski & Kole,
1993, 1994a) Accordingly, the differences in sensitiv-
ity to the oligonucleotides are even more striking for
IVS2-654 and -745 exons, the latter being partly in-
cluded in the aberrant b-globin mRNA in the absence
of the oligonucleotide (Fig+ 4, lane 1 and Table 2)+
The fact that consensus mutations at the 59 splice
sites in IVS2-654 and IVS2-705 mutants affect sensi-
tivity of the 39 splice site to ON-39cr oligonucleotide are
consistent with the concept of exon bridging (Kuo et al+,
1991; Hertel et al+, 1997) inherent in the exon definition
model (Robberson et al+, 1990)+ In this interpretation,
the ability of ON-39cr oligonucleotide to inhibit aberrant
splicing of IVS2-705con but not of IVS2-654con pre-
mRNA points to differences in bridging and recognition
of the two exons flanked by the same 39 splice site
upstream and almost identical consensus 59 splice site
downstream (Table 2)+
Whether the kinetic or steric hindrance models are
responsible for the differences in the ability of the oli-
gonucleotides to correct splicing of mutant pre-mRNAs,
it appears that the oligonucleotides compete with the
splicing factors for the target sequences and that the
interactions of the latter with pre-mRNAs vary signifi-
cantly+ Although the experiments did not identify the
competing factors, they did indicate that antisense oli-
gonucleotides may provide useful tools for modifying




Human b-globin genes carrying thalassemic mutations
IVS2-654 and -705 were cloned under the CMV promoter
as described (Dominski & Kole, 1994b)+ Additional mutants
(IVS2-745, IVS2-654con, and IVS2-705 con) were obtained
by PCR-based site-specific mutagenesis (Jones & Winistor-
fer, 1992)+ The details of the construction are available on
request+ The plasmids were cotransfected with a neomycin
resistance plasmid in complex with Lipofectamine (Gibco-
BRL) into HeLa cells and the cells stably expressing the
mutated globin genes were isolated by G-418 antibiotic se-
lection+ The cells were grown in S-MEM supplemented with
5% fetal calf and 5% horse sera+ For all experiments cells
were plated in 24-well plates at 105 cells per well 24 h
before treatment+
Oligonucleotide treatment
The 29-O-methyl-oligoribonucleoside phosphorothioates (pre-
pared and purified at Hybridon, Inc+, Cambridge, Massachu-
setts) were used+ The cells were treated with oligonucleotides
complexed with Lipofectamine for 10 h and harvested 30 h
later for subsequent analysis (see below)+ The sequences of
the oligonucleotides are listed in Table 1+ An oligonucleotide
with a random sequence (ON-ran) was used as a control in
the experiment illustrated in Figure 3A+
RNA analysis
Total RNA was isolated with TRI-Reagent (MRC, Cincinnati,
Ohio) and 200 ng were analyzed by reverse transcription and
PCR (RT-PCR) using rTth DNA polymerase as suggested by
the manufacturer (Perkin-Elmer)+ The RT-PCR products were
separated on 7+5% nondenaturing polyacrylamide gels+ The
RT-PCR was carried out with a-32P-dATP for no more than
18–22 cycles+ Under these conditions the amount of the PCR
product was proportional to the amount of input RNA as were
the relative amounts of PCR products generated from aber-
rantly and correctly spliced RNA (Chen & Chasin, 1993 and
data not shown)+ No products were detectable without the
reverse transcription step+ For analysis of aberrantly and cor-
rectly spliced products, forward and reverse primers spanned,
respectively, positions 21–43 of exon 2 (primer a, Fig+ 1A)
and positions 6–28 of exon 3 (primer c, Fig+ 1A) of the human
b-globin gene+ For RT-PCR analysis of the expression of
b-globin pre-mRNAs in HeLa cells, primer a was used in
combination with primer b (Fig+ 1A), spanning positions 119–
143 of b-globin intron 2+
Protein analysis
Immediately preceding the isolation of protein, the cells were
treated with hemin (10 mM, Fluka, Switzerland) in serum-free
medium for 4 h+ The cells were washed with HBSS and lysed
for 10 min in 75 mL of 3% SDS, 60 mM Tris, pH 6+8, 7%
sucrose, 1 mM EDTA, pH 7+4, 2 mg/mL aprotonin, 2 mg/mL
leupeptin, PMSF 100 mg/mL+ Blots of proteins separated on
a 10% Tricine-SDS polyacrylamide gel (Schägger & von Jagov,
1987) were incubated with polyclonal affinity-purified chicken
anti-human hemoglobin IgG as primary antibody and rabbit
anti-chicken horseradish peroxidase-conjugated IgG as sec-
ondary antibody (Accurate Chemicals,Westbury, New York)+
Subsequently, the blots were developed with the ECL detec-
tion system (Amersham)+
Image processing and quantitation of the data
Autoradiograms of RT-PCR gels were captured by DAGE
MTI CCD72 video camera (Michigan City, Indiana) and the
376 H. Sierakowska et al.
images were processed using NIH Image 1+61 and MacDraw
Pro 1+0 software+ The final figures were printed on a Tektronix
phaser 550 printer+ The NIH Image 1+61 was also used for
quantitation of the autoradiograms+ The percent of the correct
product relative to the sum of correct and aberrant products
was calculated and linear regression analysis of the data was
used to determine EC50 of the oligonucleotides+ Note that the
ratios of AMP content in the aberrant and correct products for
IVS2-654, -705, and -745 mutants are 1+57, 2+02, and 2+31,
respectively+ They were factored in the calculations of cor-
rection of splicing and EC50 values+
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